Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

R&D Systems™ Recombinant Human LAR Protein

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.

Manufacturer:  R&D Systems™ 9377PF050

Catalog No. 93-77P-F050

Add to cart
This item is not returnable. View return policy



The Recombinant Human LAR Protein is derived from NS0. The Recombinant Human LAR Protein has been validated for the following applications: Bioactivity.


>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.
Mouse myeloma cell line, NS0-derived Ala27-Glu1251 with a C-terminal 6-His tag, and its proteolyzed forms Ala27-Arg1169 and Gln1170-Glu1251 with a C-terminal 6-His tag
<0.10EU per 1μg of the protein by the LAL method.
Recombinant Protein
Lyophilized from a 0.2μm filtered solution in PBS with BSA and Trehalose.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
LCA-homolog, protein tyrosine phosphatase, receptor type, F, PTPRF, receptor type, F polypeptide, receptor-linked protein-tyrosine phosphatase LAR, receptor-type tyrosine-protein phosphatase F
Reconstitute at 500μg/mL in PBS.
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit